Multimodal primary treatment of metastatic prostate cancer with androgen deprivation and radiation

Anticancer Research

Volumn 36, Issue 12, 2016, Pages 6439-6447

  Joensuu, Timo ^a   Joensuu, Greetta ^a,b   Kairemo, Kalevi ^a,c   Kiljunen, Timo ^a   Riener, Maigo ^a   Aaltonen, Aili ^a   Ala Opas, Martti ^a   Kangasmäki, Aki ^a   Alanko, Tuomo ^a   Taipale, Lauri ^a,d   Hervonen, Petteri ^a,e   Bützow, Anna ^f   Virgolini, Irene ^g   Hemminki, Akseli ^a,d,h  

^a International Comprehensive Cancer Center Docrates   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f Medix Laboratoriot Oy   (Finland)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chemotherapy; Experimental approach; HDR brachytherapy; Hormone therapy; Metastatic prostate cancer; Multimodality; Non randomized; Ra 223; Radiotherapy; Retrospective; Sm 153; VMAT

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CABAZITAXEL; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DEGARELIX; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ESTRAMUSTINE; ETOPOSIDE; GEMCITABINE; GONADORELIN DERIVATIVE; IBANDRONIC ACID; LUTETIUM 177; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEBROLIZUMAB; PREDNISOLONE; RADIUM CHLORIDE RA 223; SAMARIUM 153; UNCLASSIFIED DRUG; VINBLASTINE; ZOLEDRONIC ACID; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; HUMAN; INGUINAL LYMPH NODE; INTENSITY MODULATED RADIATION THERAPY; INTESTINE FUNCTION DISORDER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; NOCTURIA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; POLLACISURIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; SUPRACLAVICULAR LYMPH NODE; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE; VOLUMETRIC MODULATED ARC THERAPY; CANCER GRADING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; YOUNG ADULT;

ADULT; AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85002050603     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11242     Document Type: Article

References (30)

1. Mohler J, Armstrong A, Bahnson R, D'Amico A, Davis B, Eastham J, Enke C, Farrington T, Higano C, Horwitz EM, Hurwitz M, Kane C, Kawachi M, Kuettel M, Lee R, Meeks J, Penson D, Plimack E, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus T, Small E, Sonpavde G, Srinivas S, Strope S and Tward J: National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer, Version 3, 2016. https://www.nccn.org/ professionals/physician-gls/pdf/prostate.pdf. Accessed September 12, 2016.
2. Aaltomaa S, Jousilahti P, Kataja V, Korpela M, Kujala P, Laato M, Lindholm P, Matikainen M, Rannikko A, Sipila R and Tammela T: Finnish Current Care Guideline. Prostate Cancer, 2015. http://www.kaypahoito.fi/web/kh/suositukset/suositus? id=hoi11060#NaN. Accessed September 12, 2016.
3. Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, Henry A, Joniau S, Lam T, Mason MD, Matveev V, van der Poel H, van der Kwast TH, Rouviere O and Wiegel T: European Association of Urology, European Society for Radiotherapy and Oncology, International Society of Geriatric Oncology. Guidelines on Prostate Cancer. 2016. http://uroweb.org/wpcontent/ uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf. Accessed September 12, 2016.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA and TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
5. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF and Andrieu JM: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 3343-3351, 2005.
6. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK and STAMPEDE investigators: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387: 1163-1177, 2016.
7. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO and TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376: 1147-1154, 2010.
8. Oefelein MG: Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 63: 1117-1121, 2004.
9. Perez CA, Cosmatos D, Garcia DM, Eisbruch A and Poulter CA: Irradiation in relapsing carcinoma of the prostate. Cancer 71: 1110-1122, 1993.
10. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F and Blute M: Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis. Eur Urol 59: 832-840, 2011.
11. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H and PROSTY study group: 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14: 117-124, 2013.
12. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB,Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI and COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005, 2011.
13. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B and PREVAIL Investigators: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424-433, 2014.
14. Muenchen HJ, Quigley MM, Pilat MJ, Lehr JE, Brumfield SK, Mahoney M and Pienta KJ: The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. Anticancer Res 20: 735-740, 2000.
15. Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E and Benoit G: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14: 1291-1298, 2003.
16. Kiljunen T, Kangasmaki A, Aaltonen A, Kairemo K, Partanen K, Joensuu G, Alanko T, Vaalavirta L and Joensuu T: VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases. Acta Oncol 54: 847-853, 2015.
17. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events. Version 4.03. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed September 12, 2016.
18. Joensuu TK: Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. Urol Int 80: 448-450, 2008.
19. Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 167: 948-51; discussion 952, 2002.
20. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y and Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer: Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115: 3437-3445, 2009.
21. Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M and Ohashi Y: Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: A multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol 134: 1385-1396, 2008.
22. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC and Bova GS: The evolutionary history of lethal metastatic prostate cancer. Nature 520: 353-357, 2015.
23. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L and Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300, 1997.
24. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA and DiPaola RS: Chemohormonal therapy in metastatic hormonesensitive prostate cancer. N Engl J Med 373: 737-746, 2015.
25. Tarish FL, Schultz N, Tanoglidi A, Hamberg H, Letocha H, Karaszi K, Hamdy FC, Granfors T and Helleday T: Castration radiosensitizes prostate cancer tissue by impairing DNA doublestrand break repair. Sci Transl Med 7: 312re11, 2015.
26. Loberg RD, Logothetis CJ, Keller ET and Pienta KJ: Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 23: 8232-8241, 2005.
27. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J and Laplanche A: Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27: 2429-2435, 2009.
28. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O and ALSYMPCA Investigators: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213-223, 2013.
29. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD and Pugh TJ: Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34: 2835-2842, 2016.
30. Anonymous: Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer. OncoLog 61(7): 5, 2016.